Neurizon Therapeutics Limited

NUZ

AU0000357261

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 11:04:13 10/04/2026 am IST			5-day change	1st Jan Change
0.0830 ^AUD	+2.47%		-2.35%	-2.35%

01/04	Neurizon Therapeutics Says Preclinical Findings Show NUZ-001 Drug Candidate Raises Protein Clearance Activity in Neuronal Systems; Shares Rise 5%	MT
16/03	Neurizon Therapeutics says Michael Thurn resigns as managing director and CEO	RE

Neurizon Therapeutics Limited Announces Results from an Independent Study Conducted in Collaboration with Tessara Therapeutics

Published on 04/01/2025 at 03:34 am IST

S&P Capital IQ

NEURIZON THERAPEUTICS LIMITED

+2.47%

Neurizon Therapeutics Limited announced that results from an independent study undertaken in collaboration with Tessara Therapeutics will be presented by the group's Principal Scientist and Alzheimer's Disease expert, Dr Mark Greenough at the AD/PD 2025 Advances in Sciences & Therapy conference on April 2nd to 3rd. The results are part of a study in ongoing collaboration with Tessara, a leading biotechnology company pioneering a new approach in 3D cell-based models of the brain, having developed its RealBrain 3D human micro-tissues technology that replicates the biological complexity of the human brain in a scalable and reproducible manner. Tessara has validated and recently launched two brain models: the ArtiBrainTM model (healthy human brain) and the ADBrainTM model (Alzheimer's disease).

Tessara has leveraged these models to explore the effect of Neurizon's lead candidate, NUZ-001. In addition, the compounds appear to offer neuroprotective effects against ferroptosis and encourage neural branching, potentially boosting plasticity by enabling neurons to form additional connections. While further research is needed to clarify the mechanisms responsible for these benefits, current data suggest that longer-term treatment may enhance network density and overall plasticity.

In humans, this could translate into tangible benefits in cognition, learning, memory, or resilience to neurodegenerative processes involved in diseases such as Alzheimer's disease, Parkinson's disease and Amyotrophic Lateral Sclerosis (ALS). As part of ongoing initiatives with Tessara, the therapeutic efficacy of NUZ-001 is now being assessed through other screening modalities, including Tessara's ADBrainTM platform, for sporadic Alzheimer's disease. Results from further testing are anticipated this quarter and will be used to assess the potential for NUZ to expand its lead asset into a broader range of indications.

Through its proprietary RealBrain®? platform, Tessara has developed the first scalable, reproducible 3D human brain micro-tissue models that closely replicate both healthy and diseased neural physiology. By enabling cost -effective, high-throughput screening and delivering predictive, human-relevant data, Tessara's approach accelerates discovery timelines, enhances the likelihood of successful clinical trials, and supports the industry-wide shift to non-animal research.

This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

Latest news about Neurizon Therapeutics Limited

01/04	Neurizon Therapeutics Says Preclinical Findings Show NUZ-001 Drug Candidate Raises Protein Clearance Activity in Neuronal Systems; Shares Rise 5%	MT
16/03	Neurizon Therapeutics says Michael Thurn resigns as managing director and CEO	RE
16/03	Neurizon Therapeutics Chief Executive Officer Resigns, Shares Down 13%	MT
05/03	Neurizon Says Pre-Clinical Data Supports Potential of Drug Candidate for Neurodegenerative Disease	MT
27/02	Neurizon Therapeutics Limited Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial	CI
25/02	Neurizon Therapeutics posts loss for half year attributable of A$5.5 million	RE
25/02	Neurizon Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2025	CI
20/01	Neurizon Therapeutics Obtains Global Trademark Protection in Major Markets	MT
20/01	Neurizon Therapeutics secures registered trademark protection for Neurizon® across all priority global markets	RE
02/01	FDA Denies Neurizon Therapeutics' Request for Fast Track Designation for ALS Treatment Candidate	MT
02/01	Neurizon Therapeutics says US FDA denies Fast Track designation for NUZ-001	RE
23/12	Neurizon Therapeutics says firm commitments to raise A$7.1 million via placement	RE
23/12	Neurizon Therapeutics to Raise Over AU$7 Million via Share Placement; Shares Hit 52-Week Low	MT
19/12	Neurizon Therapeutics seeks trading halt	RE
11/12	Neurizon Says US FDA Clears Use of Drug Candidate in ALS Clinical Trial	MT

Chart Neurizon Therapeutics Limited

Duration

Period

NUZ: Dynamic Chart

Company Profile

Neurizon Therapeutics Ltd, formerly PharmAust Limited, is an Australia-based clinical-stage biotechnology company. The Company is engaged in advancing treatments for neurodegenerative diseases. The Company is focused on developing its lead drug candidate, NUZ-001, for the treatment of Amyotrophic Lateral Sclerosis (ALS), which is the common form of motor neuron disease. ALS is a devastating neurodegenerative condition that primarily affects nerve cells that control voluntary muscles.

Employees

Sector

Pharmaceuticals

More about the company